Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Pharmacological Characterization of ZD6021: A Novel, Orally Active Antagonist of the Tachykinin Receptors

William L. Rumsey, David Aharony, Russell A. Bialecki, Brian M. Abbott, Herbert G. Barthlow, Robert Caccese, Smita Ghanekar, David Lengel, Michelle McCarthy, Barbara Wenrich, Bradley Undem, Cyrus Ohnmacht, Ashok Shenvi, Jeffrey S. Albert, Fred Brown, Peter R. Bernstein and Keith Russell
Journal of Pharmacology and Experimental Therapeutics July 2001, 298 (1) 307-315;
William L. Rumsey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Aharony
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell A. Bialecki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian M. Abbott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Herbert G. Barthlow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Caccese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Smita Ghanekar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Lengel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle McCarthy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Wenrich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley Undem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cyrus Ohnmacht
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashok Shenvi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey S. Albert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred Brown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter R. Bernstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith Russell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The tachykinins, substance P, neurokinin A, and neurokinin B, have been implicated in many diseases. The present study evaluated the pharmacological properties of a novel tachykinin antagonist ZD6021 [3-cyano-N-((2S)-2-(3,4-dichlorophenyl)-4-[4-[2-(methyl-(S)-sulfinyl)-phenyl]piperidino]butyl)-N-methyl-]-napthamide]. The affinity (Ki) of ZD6021 for the cloned human neurokinin (NK)1, NK2, and NK3 receptors was 0.12 ± 0.01, 0.64 ± 0.08, and 74 ± 13 nM, respectively. Mucin secretion by Chinese hamster ovary cells transfected with the human NK1 receptor was dose dependently inhibited by ZD6021: pIC50 = 7.6 ± 0.1. For NK1 and NK2 receptors, the agonist concentration-response curves using isolated tissues were displaced rightward in the presence of ZD6021: rabbit pulmonary artery, pA2 = 8.7 and 8.5; human pulmonary artery and bronchus, pKB = 8.9 ± 0.4 and 7.5 ± 0.2, at 10−7 M, respectively. Senktide-induced contractions of isolated guinea pig ileum were also blocked by low concentrations of ZD6021. Oral administration of ZD6021 to guinea pigs dose dependently attenuated tracheal extravasation of plasma proteins induced by the NK1 receptor agonist Ac-[Arg6,Sar9,Met(O2)11]-SP(6-11), ED50 = 0.8 μmol/kg, and bronchoconstriction, elicited by the NK2 receptor agonist [β-Ala8]-NKA(4-10), ED50 = 20 μmol/kg. Potency was unaffected by feeding. After oral administration of ZD6021, the time to peak activity was 150 min for the NK1 receptor and 60 min for the NK2 receptor with pharmacodynamic half-lives of 280 and 458 min, respectively. These data indicate that ZD6021 is a potent, orally active antagonist of all three tachykinin receptors. This compound may be useful for future studies of tachykinin-related pathology such as asthma.

Footnotes

  • Abbreviations:
    SP
    substance P
    NKA
    neurokinin A
    NKB
    neurokinin B
    PPT
    preprotachykinin
    ZD6021
    3-cyano-N-((2S)-2-(3,4-dichlorophenyl)-4-[4-[2-(methyl-(S)-sulfinyl)phenyl]piperidino]butyl)-N-methyl-]-napthamide
    ASM-SP
    Ac-[Arg6, Sar9, Met(O2)11] substance P6-11
    BANK
    β-ala-8NKA(4-10)
    GL
    airway conductance
    1/Rp
    reciprocal of pulmonary resistance
    MEL
    murine erythroleukemia
    • Received November 17, 2000.
    • Accepted April 9, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 298 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 298, Issue 1
1 Jul 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Characterization of ZD6021: A Novel, Orally Active Antagonist of the Tachykinin Receptors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Pharmacological Characterization of ZD6021: A Novel, Orally Active Antagonist of the Tachykinin Receptors

William L. Rumsey, David Aharony, Russell A. Bialecki, Brian M. Abbott, Herbert G. Barthlow, Robert Caccese, Smita Ghanekar, David Lengel, Michelle McCarthy, Barbara Wenrich, Bradley Undem, Cyrus Ohnmacht, Ashok Shenvi, Jeffrey S. Albert, Fred Brown, Peter R. Bernstein and Keith Russell
Journal of Pharmacology and Experimental Therapeutics July 1, 2001, 298 (1) 307-315;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleNEUROPHARMACOLOGY

Pharmacological Characterization of ZD6021: A Novel, Orally Active Antagonist of the Tachykinin Receptors

William L. Rumsey, David Aharony, Russell A. Bialecki, Brian M. Abbott, Herbert G. Barthlow, Robert Caccese, Smita Ghanekar, David Lengel, Michelle McCarthy, Barbara Wenrich, Bradley Undem, Cyrus Ohnmacht, Ashok Shenvi, Jeffrey S. Albert, Fred Brown, Peter R. Bernstein and Keith Russell
Journal of Pharmacology and Experimental Therapeutics July 1, 2001, 298 (1) 307-315;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Oxysterols and ethanol
  • P-glycoprotein Apical Efflux Ratio for Compound Optimization
  • Pharmacology of Carbamate Insecticides at MT1 & MT2
Show more Neuropharmacology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics